Mihael Hristos Polymeropoulos Purchases 20,000 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos acquired 20,000 shares of the firm’s stock in a transaction dated Friday, May 16th. The shares were purchased at an average price of $4.22 per share, with a total value of $84,400.00. Following the completion of the transaction, the chief executive officer now owns 2,315,731 shares of the company’s stock, valued at $9,772,384.82. This trade represents a 0.87% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Mihael Hristos Polymeropoulos also recently made the following trade(s):

• On Wednesday, March 5th, Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock. The shares were purchased at an average cost of $5.02 per share, for a total transaction of $50,200.00.
• On Friday, February 28th, Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock. The stock was acquired at an average cost of $4.76 per share, with a total value of $47,600.00.
• On Tuesday, February 25th, Mihael Hristos Polymeropoulos bought 10,000 shares of Vanda Pharmaceuticals stock. The shares were acquired at an average price of $4.46 per share, for a total transaction of $44,600.00.

Vanda Pharmaceuticals Stock Performance

Vanda Pharmaceuticals stock traded up $0.15 during mid-day trading on Monday, reaching $4.31. The stock had a trading volume of 547,638 shares, compared to its average volume of 722,826. The firm has a market capitalization of $254.01 million, a PE ratio of -13.47 and a beta of 0.69. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.81 and a fifty-two week high of $6.75. The stock’s 50-day simple moving average is $4.43 and its 200-day simple moving average is $4.63.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The business had revenue of $50.04 million during the quarter, compared to analyst estimates of $45.13 million. On average, research analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Quantinno Capital Management LP purchased a new stake in shares of Vanda Pharmaceuticals in the fourth quarter worth approximately $48,000. Linden Thomas Advisory Services LLC bought a new stake in Vanda Pharmaceuticals during the first quarter worth $49,000. Nations Financial Group Inc. IA ADV purchased a new stake in Vanda Pharmaceuticals in the 1st quarter valued at $67,000. XTX Topco Ltd bought a new position in Vanda Pharmaceuticals during the 4th quarter valued at $69,000. Finally, Virtu Financial LLC bought a new stake in shares of Vanda Pharmaceuticals in the 1st quarter worth $72,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Analysts Set New Price Targets

VNDA has been the subject of a number of research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 target price on shares of Vanda Pharmaceuticals in a report on Wednesday, May 14th. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.